Enhancing Lung Cancer Outcomes Through Preventative and Early Detection Strategies in the United States
Vivien Wittstruck
Freedom High School, Oakley, USA
Publication date: July 10, 2026
Freedom High School, Oakley, USA
Publication date: July 10, 2026
DOI: http://doi.org/10.34614/JIYRC2026I35
ABSTRACT
Lung cancer is the leading cause of cancer-related death worldwide, though it is often detected at advanced stages when treatment is limited. Preventive and early detection strategies, such as low-dose computed tomography (LDCT) screening, offer opportunities to shift diagnoses toward earlier, more treatable stages. This systematic review synthesized 14 U.S.-based studies (2010–2025) following PRISMA guidelines. Findings show LDCT screening reduces lung cancer mortality by up to 24% among high-risk populations, with further benefits when combined with education modules such as smoking cessation interventions. Expanding screening eligibility beyond traditional criteria and incorporating novel methods, such as lung nodule detection and artificial intelligence, may improve outcomes and address disparities. Further barriers remain that also must be addressed, such as restricted insurance coverage and limited accessibility for non-traditional risk groups. Policy changes and preventive initiatives are needed to enhance early detection and reduce disparities to ultimately improve survival outcomes.
Lung cancer is the leading cause of cancer-related death worldwide, though it is often detected at advanced stages when treatment is limited. Preventive and early detection strategies, such as low-dose computed tomography (LDCT) screening, offer opportunities to shift diagnoses toward earlier, more treatable stages. This systematic review synthesized 14 U.S.-based studies (2010–2025) following PRISMA guidelines. Findings show LDCT screening reduces lung cancer mortality by up to 24% among high-risk populations, with further benefits when combined with education modules such as smoking cessation interventions. Expanding screening eligibility beyond traditional criteria and incorporating novel methods, such as lung nodule detection and artificial intelligence, may improve outcomes and address disparities. Further barriers remain that also must be addressed, such as restricted insurance coverage and limited accessibility for non-traditional risk groups. Policy changes and preventive initiatives are needed to enhance early detection and reduce disparities to ultimately improve survival outcomes.
